October 25, 2024. T-CURX' CEO and CMO present as invited speakers at the 3rd largest hematology congress worldwide, HEMO2024 in Sao-Paolo, Brazil

Ulf Grawunder, PhD, CEO, and Michael Hudecek, MD, CMO of T-CURX were invited to present their innovations at T-CURX and research at the University Hospital Würzburg at the annual hematology congress of the Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy (ABHH), the 3rd largest hematology congress in the world, taking place in Sao Paolo, Brazil

The Brazilian Congress of Hematology, Hemotherapy, and Cellular Therapy (HEMO 2024), is organized by the Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy (ABHH) and will take place in-person from October 23 to 26, 2024, between Wednesday and Saturday at the Transamerica Expo Center, in São Paulo, Brazil. After US-based ASH congress of the American Society for Hematology and the European EHA congress of the European Hematology Association, HEMO is the 3rd largest hematology congress in the world with about 7'800 delegates from Academia and Industry attending. Information about the congress can be found on the conference web-site: https://hemo.org.br/2024/index.ingles-2024.php. 

T-CURX co-founders Ulf Grawunder, PhD (CEO) and Michael Hudecek, MD (CMO) have been invited as guest speakers in a session on CAR-T cells on Friday, October 25, 2024. Michael Hudecek's presentation entitled "Predicting efficacy and toxicity associated engineered T cell-associated with next-generation models" is scheduled for 9:10-9:30 a.m. and Ulf Grawunder's presentation entitled "In vivo CAR-T therapies: challenges and perspectives" is scheduled for 9:30-9:50 a.m. in the session "Advanced Cell Therapy" taking place in the "Arena Hemo Talks". Both presentations were followed by a panel discussion with Michael and Ulf as panelists. 

In addition, Michael Hudecek, was further invited to give a presentation on Saturday, October 26, 2024 in the "ABHH - European Hematology Association (EHA) Joint Session: Emerging Gene-Engineering Technologies and Artificial Intelligence in Hematology and Cell Therapy". Michael presents about "Advanced CAR T-cell products in hematologic malignacies and beyond" on October from 9:10-9:50 a.m. in the Auditorium 2.